MarketPulse

hepatitis B

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aligos Scores $25M Upfront in China Deal for Hepatitis B Drug

Aligos Therapeutics licenses pevifoscorvir to Xiamen Amoytop for Greater China development, receiving $25M upfront and up to $420M in milestones.
ALGSclinical developmentpevifoscorvir sodium
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Pegasys Market Poised for Growth Despite DAA Competition and Tariff Headwinds

Pegasys market projected for growth via rising hepatitis B prevalence and indication expansion, though direct-acting antivirals and tariff pressures pose challenges. Asia-Pacific represents fastest-growing region.
PFERHHBYGRFSemerging marketsoncology